STOCK TITAN

Pacira BioSciences (PCRX) SEC Filings, Nov 12-17, 2026

PCRX NASDAQ

Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.

The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.

Rhea-AI Summary

Pacira BioSciences, Inc. director Thomas G. Wiggans disposed of a directly held stock option covering 32,675 shares on November 17, 2026, the merger’s effective date. The option was canceled and converted into a cash right calculated using the $36.50 per-share offer price less its $23.42 per-share exercise price, subject to applicable tax withholding. Wiggans reported zero options remaining after the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Pacira BioSciences, Inc. (PCRX) Senior Vice President, Finance Lauren Riker reported merger-related dispositions on November 17, 2026, when the cash tender offer and merger became effective. Her 6,881 shares were converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest. Another 55,403 shares issuable under restricted stock unit awards were canceled and converted into a right to receive cash based on the $36.50 offer price, subject to tax withholding. The reported options had exercise prices above $36.50 and were canceled without consideration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Pacira BioSciences, Inc. director Laura Brege disposed of 23,715 common shares in the cash tender offer on November 17, 2026, at $36.50 per share. The offer was part of Viatris Inc.’s acquisition; at the merger’s effective time, Pacira became Viatris’ wholly owned subsidiary.

Her 6,405 restricted stock unit award shares were canceled and converted into a cash right based on the $36.50 offer price, subject to tax withholding. Ten option tranches were canceled and converted into cash only where the offer price exceeded the exercise price; options with exercise prices at or above $36.50 were canceled for no consideration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Pacira BioSciences, Inc. Chief Medical Officer Jonathan Slonin reported a disposition to the issuer of 216,729.67 common shares at the $36.50-per-share offer price on November 17, 2026, when the merger became effective; his reported direct holdings afterward were zero. Each share converted into a right to receive the offer price, net of applicable withholding taxes and without interest. No Rule 10b5-1 plan is reported.

The report also lists six option positions disposed of in connection with the merger. Options with exercise prices below $36.50 were canceled and converted into cash based on the difference between the offer price and exercise price; options at or above $36.50 were canceled without consideration. Pacira survived the merger as a wholly owned subsidiary of Viatris.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Pacira BioSciences, Inc. (PCRX) completed its merger with Viatris on November 17, 2026, becoming Viatris’ wholly owned subsidiary. Each eligible outstanding Pacira share converted into the right to receive $36.50 in cash, subject to applicable withholding taxes and without interest. Shares held by Pacira, its subsidiaries, Viatris or its subsidiaries, and shares with perfected appraisal rights were excluded.

The transaction required approximately $1.69 billion to pay for shares in the offer and merger and repay certain Pacira debt; the amount excludes deal fees and expenses and Pacira cash and cash equivalents assumed by Viatris. Pacira repaid $96,392.50 outstanding under its credit agreement and terminated the agreement and commitments; related liens will be released. Its $287.5 million of 2.125% convertible notes due 2029 now convert only into cash, not Pacira shares.

For notes validly surrendered from November 17, 2026 through 5:00 p.m. New York City time on January 8, 2027, the cash conversion amount is $1,103.8914 per $1,000 principal, including the make-whole increase. After that period, when notes are otherwise convertible, the amount is $922.5448 per $1,000 principal. Cash is payable on the tenth Business Day after conversion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Pacira BioSciences, Inc. (PCRX) completed its merger with Viatris on November 17, 2026, after Viatris subsidiary Purchaser completed a cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. The offer expired November 16 and was not extended. Holders validly tendered 32,929,780 shares; those shares, together with shares already owned by Purchaser and its affiliates, represented approximately 66.46% of Pacira’s issued and outstanding shares at expiration, satisfying the Minimum Condition.

Purchaser accepted the validly tendered shares for payment on November 17, and the merger closed that day under Section 251(h) without a Pacira stockholder vote. Each outstanding share immediately before the merger, except shares held by Pacira, Viatris-related entities, and stockholders exercising appraisal rights, converted into the right to receive the offer price. Pacira survived as a wholly owned Viatris subsidiary; its shares will be delisted from the Nasdaq Global Select Market and deregistered under the Exchange Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
Rhea-AI Summary

Pacira BioSciences, Inc. (PCRX) is the target of a cash tender offer by Viatris subsidiary Peach Purchaser Sub for all outstanding common shares at $36.50 per share, net of applicable withholding taxes and without interest. The offer expired as scheduled on November 16, 2026; 32,929,780 shares, approximately 66.46% of shares outstanding immediately before expiration, were validly tendered and not withdrawn. The buyer accepted all such shares for payment on November 17, 2026, with payment to be made promptly under the offer terms.

The tendered shares, together with shares then owned by the buyer and its affiliates, satisfied the Minimum Condition, excluding guaranteed-delivery shares not yet received for that condition. The remaining merger conditions were satisfied or waived, and Peach Purchaser Sub will merge into Pacira on November 17, 2026, without a Pacira stockholder vote. At the merger’s effective time, eligible outstanding shares convert into the right to receive the offer price; specified company- and buyer-held shares are canceled, while properly perfected appraisal-right shares are excluded. After the merger, Pacira shares will be delisted and cease trading on the Nasdaq Global Select Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

Pacira BioSciences, Inc. (PCRX) is the subject of a Nasdaq Form 25 notice concerning the voluntary withdrawal of its common stock from listing and registration on Nasdaq. The notice states that Pacira complied with Nasdaq’s rules and the requirements for voluntary withdrawal, and Nasdaq certified that it had reasonable grounds to believe the Form 25 filing requirements were met.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Pacira BioSciences, Inc. (PCRX) reported that on November 6, 2026, the Ninth Circuit reversed a district court judgment in part, holding Pacira owes royalties on EXPAREL made using its 200-liter process and directing the district court to enter judgment for RDF on that claim. The appeals court also remanded the calculation of prejudgment interest RDF owes Pacira on the 45-liter EXPAREL portion of the judgment.

Before the appeal, the district court had ordered RDF to repay $23.1 million and awarded $5.2 million in statutory interest; Pacira said it received a $28.3 million cash payment in July 2025. Pacira said it is evaluating its legal options and cannot predict the outcome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
Rhea-AI Summary

Pacira BioSciences, Inc. (PCRX) is the subject of a tender offer by Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., for all outstanding Pacira shares at $36.50 per share in cash, net of applicable withholding taxes and without interest, on the terms and subject to the conditions of the Merger Agreement.

As of November 12, 2026, two purported Pacira stockholders, Carroll and Burke, had filed complaints in New York state court concerning merger disclosures, naming Pacira and each Pacira board member as defendants. The Pacira Defendants had not been served with the complaints. Pacira had also received 15 demand letters, including two draft complaints, generally seeking additional information about the merger disclosures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
ownership

FAQ

How many Pacira BioSciences (PCRX) SEC filings are available on StockTitan?

StockTitan tracks 124 SEC filings for Pacira BioSciences (PCRX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Pacira BioSciences (PCRX)?

The most recent SEC filing for Pacira BioSciences (PCRX) was filed on November 17, 2026.